Radius Health, a biopharmaceutical company that has commercialized an osteoporosis drug and is developing new medicines for cancer and rare diseases, has reached an agreement to be acquired by two private equity firms in an $890 million deal. According to financial terms announced Thursday, Gurnet Point Capital and Patient Square Capital will acquire all Radius shares for $10 each. […]
